Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Gefurulimab by Alexion Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval
Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Gefurulimab?
Gefurulimab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Myasthenia Gravis. According to Globaldata,...
Gefurulimab by Alexion Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval
Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...